Doing it our way now: the approach this company pioneered is becoming the market's way
The model's full reasoning — Q1 2022 call → NOWe need answer YES/NO. Need analyze transcript. Question: Does management describe that company's way of doing things is being adopted/copied/moved toward by others, validating? Need only transcript. We need look for any statements. Management discusses ModeX multi-specific antibodies, platform. Do they say others following? Elias says "we have assembled top management team...". "many of these programs have also garnered strong interest from other pharmaceutical companies for potential collaborations, which we are exploring." That's interest, not adoption/copying. No mention competitors copying. BioReference: "Our commercial payer interactions continue to be successful with preferred status with Aetna...". No. "Scarlet... Teladoc... MVP" partnerships, not copying. "Reach initiative" cost reductions. No. Maybe "we believe this is another step towards unlocking inherent value" no. Need answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| GGR | Gogoro Inc. | Q1 2023 | 2023-05-11 | D |
| TGT | Target Corporation | Q4 2022 | 2023-02-28 | C |
| ORAN | Orange SA | Q2 2018 | 2018-07-26 | B |
| USFD | US Foods Holding Corp. | Q1 2018 | 2018-05-12 | C |
| SHOO | Steven Madden, Ltd. | Q1 2017 | 2017-04-21 | C |
AES · Q1 2024 → YESThe question is: Does management describe that the WAY THIS COMPANY DOES THINGS is NOW BEING ADOPTED, COPIED, OR MOVED TOWARD BY OTHERS IN ITS MARKET, so that the company's own way of doing things is ...
GGR · Q1 2023 → YESThe question is: Does management describe that the way this company does things is now being adopted, copied, or moved toward by others in its market?
TGT · Q4 2022 → YESThe question is: Does management describe that the way this company does things is now being adopted, copied, or moved toward by others in its market?